Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression

Open access
Cheng, Qingqing, Huang, Jihan, Xu, Ling, Li, Yunfei, Li, Huafang, Shen, Yifeng, Zheng, Qingshan, Li, Lujin · 2020 · International Journal of Neuropsychopharmacology

Abstract

Objective: Model-based meta-analysis was used to describe the time-course and dose-effect relationships of antidepressants and also simultaneously investigate the impact of various factors on drug efficacy. Methods: This study is a reanalysis of a published network meta-analysis. Only placebo-controlled trials were included in this study. The change rate in depression rating scale scores from baseline was used as an efficacy indicator because a continuous variable is more likely to reflect subtle differences in efficacy between drugs. Results: A total 230 studies containing 64 346 patients were included in the analysis. The results showed that the number of study sites (single or multi-center) and the type of setting (inpatient or noninpatient) are important factors affecting the efficacy of antidepressants. After deducting the placebo effect, the maximum pure drug efficacy value of inpatients was 18.4% higher than that of noninpatients, and maximum pure drug efficacy value of single-center trials was 10.2% higher than that of multi-central trials. Amitriptyline showed the highest drug efficacy. The remaining 18 antidepressants were comparable or had little difference. Within the approved dose range, no significant dose-response relationship was observed. However, the time-course relationship is obvious for all antidepressants. In terms of safety, with the exception of amitriptyline, the dropout rate due to adverse events of other drugs was not more than 10% higher than that of the placebo group. Conclusion: The number of study sites and the type of setting are significant impact factors for the efficacy of antidepressants. Except for amitriptyline, the other 18 antidepressants have little difference in efficacy and safety.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyz062

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Model-based meta-analysis of eligible comparisons for efficacy. Width of the lines is proportional to the number of arms comparing every pair of treatments. Size of every circle is proportional to the number of randomly assigned participants (i.e., sample size).
Figure 1. Model-based meta-analysis of eligible comparisons for efficacy. Width of the lines is proportional to the number of arms comparing every pair of treatments. Size of every circle is proportional to the number of randomly assigned participants (i.e., sample size).CC BY-NC · PubMed Central
Figure 2. Visual predictive check of the final model for each treatment. The points represent the observed efficacy data and the symbol size is proportional to the sample size. The solid lines are the model predicted 95% confidence interval (CI) of each treatment. The dotted line is the median value of the model predicted efficacy.
Figure 2. Visual predictive check of the final model for each treatment. The points represent the observed efficacy data and the symbol size is proportional to the sample size. The solid lines are the model predicted 95% confidence interval (CI) of each treatment. The dotted line is the median value of the model predicted efficacy.CC BY-NC · PubMed Central
Figure 3. Typical predicted pure efficacy of each drug (red lines) and the corresponding efficacy ratio compared with the Emax_drug value (bule lines) at each time points.
Figure 3. Typical predicted pure efficacy of each drug (red lines) and the corresponding efficacy ratio compared with the Emax_drug value (bule lines) at each time points.CC BY-NC · PubMed Central
Figure 4. Dose-effect relationship of each drug. Horizontal error bars represent the SD of doses after the combination of similar doses. The vertical error bars represent the SD of the predicted pure efficacy of drugs at week 8 after the combination of same doses.
Figure 4. Dose-effect relationship of each drug. Horizontal error bars represent the SD of doses after the combination of similar doses. The vertical error bars represent the SD of the predicted pure efficacy of drugs at week 8 after the combination of same doses.CC BY-NC · PubMed Central
Figure 5. The predicted pure efficacy of each drug at week 8 (A) and the risk difference of adverse events between each drug and placebo (B). The error bar represents 95% confidence interval (CI) of the point estimate, the blue shadow area represents the distribution of efficacy (A) or adverse events (B) of the best drug, respectively.
Figure 5. The predicted pure efficacy of each drug at week 8 (A) and the risk difference of adverse events between each drug and placebo (B). The error bar represents 95% confidence interval (CI) of the point estimate, the blue shadow area represents the distribution of efficacy (A) or adverse events (B) of the best drug, respectively.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 38

Metadata

Authors
Cheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L.
Affiliations
  • Shanghai University of Traditional Chinese Medicine (CN)
  • Shanghai Mental Health Center (CN)
Corresponding author
  • Zheng, Qingshan
  • Li, Lujin
Venue
International Journal of Neuropsychopharmacology
Published
2019-11-27
Volume
23
Issue
2
Pages
76-87
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W2989897972
Cited by
38
References
40
Citations by year
2026: 2 · 2025: 4 · 2024: 11 · 2023: 8 · 2022: 4 · 2021: 3 · 2020: 6
FWCI
2.01
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Shanghai Municipal Health Planning Commission (2018YQ48)
  • The Drug Innovation Major Project (2018ZX09734005-001-002, 2018ZX09734005-006, 2018ZX09711001-009-001, 2018ZX09731016, 2017ZX09304003)
  • Science and Technology Innovation Action Plan of Shanghai (17401970900)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
Keywords
antidepressants, major depressive disorder, acute depression, dose-response relationship, placebo effect, amitriptyline, inpatient vs outpatient treatment, antidepressant safety, adverse events
MeSH terms
Network Meta-Analysis, Network Meta-Analysis As Topic, Network Meta-Analysis as Topic, Acute Disease, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Models, Statistical, Outcome Assessment, Health Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. https://app.cochat.ai/papers/10.1093/ijnp/pyz062
The paper
Cheng, Q., Huang, J., Xu, L., Li, Y., Li, H., Shen, Y., Zheng, Q., & Li, L. (2020). Analysis of Time-Course, Dose-Effect, and Influencing Factors of Antidepressants in the Treatment of Acute Adult Patients With Major Depression. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyz062

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.